Heartache in a Bottle: Understanding Alcoholic Cardiomyopathy.
Level 3 - non-randomized controlled study
Systematic review of observational and preclinical studies
PubMed 37664402 · doi:10.7759/cureus.42886
What was done
A systematic review was conducted via PubMed to identify studies published between 2013 and 2023 examining alcoholic cardiomyopathy (ACM) and cardiac dysfunction related to alcohol abuse in human subjects or animal models. Case reports, letters, editorials, and reviews not specifically addressing ACM were excluded. The Cochrane risk-of-bias tool was used for clinical trials. A total of 18 studies were included.
What was found
The occurrence of ACM significantly increased with consumption of over 80 g of alcohol per day for at least five years. ACM was associated with cellular, structural, and histological cardiac muscle damage, though specific distinguishing histological markers have not been defined. Diagnosis remains exclusionary in individuals with prolonged alcohol abuse, with total abstinence forming the primary treatment alongside standard heart failure management.
Why it matters
It reinforces a clinically relevant threshold (>80 g/day for ≥5 years) for alcohol-induced cardiomyopathy and underscores that diagnosis is by exclusion and treatment relies on abstinence.
Limits
The review searched only one database (PubMed) and included a heterogeneous mix of human observational studies and animal models without meta-analysis or reporting of quantitative risk estimates and confidence intervals in the abstract.
Cited by
- supports Most patients who present with alcoholic cardiomyopathy have consumed six to eight drinks per day for 20 years or more.